Antabio SAS announced the hiring of biotech executives to its management team. 

Starting January 1st 2018 and on a part-time basis, Gordon Waldron will lead Finance, Carole Sable will oversee Clinical Strategy, Helmuth van Es will direct Business Development and David Lathbury will manage CMC activities.

These executives have built strong track records directing and growing innovative biotech companies, forging alliances, maximizing shareholder value and taking products through pre-clinical and clinical development to market. 

The appointments come soon after the first closing of a Series A financing round and notification that Antabio has been selected as one of 18 out of 368 international candidates for a CARB-X subsidy award of up to $8.9 million.

Antabio’s lead molecule is now in preclinical development and is expected to enter the clinic in early 2019 with fast track to potential market approval by 2023. 

Marc Lemonnier, Antabio’s chief executive officer, said, “We are thrilled to have attracted such high caliber talent. These new additions, along with the expertise already in house through Martin Everett (CSO), Magdalena Zalacain (head of preclinical development) and David Davies (head of chemistry), give Antabio the broad skill sets and high quality international leadership team needed as we embark on the next phase of our growth and move our antibacterial resistance pipeline towards the clinic”.